<DOC>
	<DOCNO>NCT02721459</DOCNO>
	<brief_summary>The main purpose study determine maximum tolerate dose ( MTD ) recommend phase II dose ( RP2D ) XL888 administer orally vemurafenib plus cobimetinib participant BRAF V600 mutate melanoma evaluate safety tolerability combination .</brief_summary>
	<brief_title>XL888 + Vemurafenib + Cobimetinib Unresectable BRAF Mutated Stage III/IV Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<criteria>Must 18 year age . All race ethnicity eligible upper limit age specify . Must cytologically histologicallyconfirmed unresectable melanoma harbor BRAF V600 E K mutation determine pyrosequencing assay equivalent genotyping assay Clinical Laboratory Improvement Amendments ( CLIA ) certify laboratory , meet one follow AJCC stag criterion : 1 . ) American Joint Committee Cancer ( AJCC ) stage IV ( Tany , Nany , M1a , b , c ) ; 2 . ) AJCC stage IIIB IIIC unresectable nodal/locoregional involvement . Adequate hepatic , renal , bone marrow function parameter obtain within 2 week prior initiation study treatment . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 . Willing give write informed consent per institutional guideline must able adhere dose visit schedule . Negative serum pregnancy test within 7 day prior commencement dose premenopausal woman . Women nonchildbearing potential may include without serum pregnancy test either surgically sterile postmenopausal ≥1 year . Fertile men woman must use effective method contraception treatment least 6 month completion treatment direct physician . Treatmentnaïve previously treat patient include ; however , patient may receive BRAF , Mitogen Activated Kinase ( MEK ) HSP90 inhibitor past . May receive prior systemic and/or radiation therapy . All adverse event associate prior systemic therapy radiation therapy must resolve ≤ Grade 1 prior start study . Must measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 . Women pregnant , intend become pregnant nursing . Previously treat BRAF , MEK HSP90 inhibitor therapy . Uncontrolled intercurrent illness include , limited , ongoing active infection , psychiatric illness/social situation would limit compliance study requirement . HIVpositive patient combination antiretroviral therapy . Potential participant untreated uncontrolled brain metastasis evidence leptomeningeal disease . Patients asymptomatic brain metastasis previously treat brain metastasis stable ( i.e. , require corticosteroid ) time study start eligible . Previous malignancy exclusion provide malignancy consider control , patient concomitant anticancer drug therapy , target lesion melanoma clearly define response assessment . History malabsorption condition would interfere absorption study drug . The following foods/supplements prohibit least 7 day prior initiation study treatment : St. John 's wort hyperforin ( potent cytochrome P450 CYP3A4 enzyme inducer ) ; Grapefruit juice ( potent cytochrome P450 CYP3A4 enzyme inhibitor ) . Ocular : History evidence retinal pathology ophthalmologic examination consider risk factor neurosensory retinal detachment , retinal vein occlusion ( RVO ) , neovascular macular degeneration . Cardiac : History clinically significant cardiac dysfunction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>unresectable melanoma</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>AJCC melanoma stag</keyword>
	<keyword>American Joint Committee Cancer ( AJCC )</keyword>
	<keyword>BRAF V600 E mutation</keyword>
	<keyword>BRAF V600 K mutation</keyword>
</DOC>